NO970468L - Jernholdige nanopartikler med dobbelt belegning og deres anvendelse i diagnostikk og terapi - Google Patents

Jernholdige nanopartikler med dobbelt belegning og deres anvendelse i diagnostikk og terapi

Info

Publication number
NO970468L
NO970468L NO970468A NO970468A NO970468L NO 970468 L NO970468 L NO 970468L NO 970468 A NO970468 A NO 970468A NO 970468 A NO970468 A NO 970468A NO 970468 L NO970468 L NO 970468L
Authority
NO
Norway
Prior art keywords
diagnostics
therapy
double coating
ferrous nanoparticles
ferrous
Prior art date
Application number
NO970468A
Other languages
English (en)
Other versions
NO970468D0 (no
NO314785B1 (no
Inventor
Mayk Kresse
Detlef Pfefferer
Ruediger Lawaczek
Susanne Wagner
Wolfgang Ebert
Volker Elste
Wolfhard Semmler
Matthias Taupitz
Josef Gaida
Anja Herrmann
Monika Jukl
Udo Swiderski
Original Assignee
Diagnostikforschung Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnostikforschung Inst filed Critical Diagnostikforschung Inst
Publication of NO970468D0 publication Critical patent/NO970468D0/no
Publication of NO970468L publication Critical patent/NO970468L/no
Publication of NO314785B1 publication Critical patent/NO314785B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
    • G01N2400/14—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar alpha-D-Glucans, i.e. having alpha 1,n (n=3,4,6) linkages between saccharide units, e.g. pullulan
    • G01N2400/22—Dextran
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/20—Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/30—Magnetic particle immunoreagent carriers the magnetic material being dispersed in the polymer composition before their conversion into particulate form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19970468A 1994-08-04 1997-02-03 Jernholdige nanopartikler med dobbelt belegning og deres anvendelse i diagnostikk og terapi NO314785B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4428851A DE4428851C2 (de) 1994-08-04 1994-08-04 Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
PCT/DE1995/000924 WO1996004017A1 (de) 1994-08-04 1995-07-10 Eisen enthaltende nanopartikel mit doppeltem coating und anwendung in der diagnostik und therapie

Publications (3)

Publication Number Publication Date
NO970468D0 NO970468D0 (no) 1997-02-03
NO970468L true NO970468L (no) 1997-04-02
NO314785B1 NO314785B1 (no) 2003-05-26

Family

ID=6525704

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19970468A NO314785B1 (no) 1994-08-04 1997-02-03 Jernholdige nanopartikler med dobbelt belegning og deres anvendelse i diagnostikk og terapi

Country Status (13)

Country Link
US (3) US6048515A (no)
EP (1) EP0773796A1 (no)
JP (1) JPH10503496A (no)
KR (1) KR100278513B1 (no)
CN (1) CN1103604C (no)
AU (1) AU703042B2 (no)
CA (1) CA2195318C (no)
DE (1) DE4428851C2 (no)
HU (1) HUT77993A (no)
IL (1) IL114713A (no)
NO (1) NO314785B1 (no)
WO (1) WO1996004017A1 (no)
ZA (1) ZA956005B (no)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
ATE211950T1 (de) * 1996-08-05 2002-02-15 Schering Ag Vorrichtung und verfahren zur abtrennung magnetischer materialien aus pharmazeutischen zubereitungen, deren ausgangs- oder zwischenprodukten sowie mit hilfe dieser vorrichtung hergestellte mittel
FR2753902B1 (fr) * 1996-09-27 1999-04-02 Ioualalen Karim Nouveau type de matrice ionique biodegradable de polarite interne modulable a polymere greffe
DE19652374A1 (de) * 1996-12-04 1998-06-10 Schering Ag Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
US6168780B1 (en) * 1997-02-26 2001-01-02 Institut Fuer Physikalische Hochtechnologie E.V. Marker for determining its position in a cavity inside the organism of a living being
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
EP1090293B2 (en) 1998-06-24 2019-01-23 Illumina, Inc. Decoding of array sensors with microspheres
US6470220B1 (en) * 1999-03-29 2002-10-22 The Regents Of The University Of California Diagnosis and treatment of cancers using in vivo magnetic domains
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US6544732B1 (en) * 1999-05-20 2003-04-08 Illumina, Inc. Encoding and decoding of array sensors utilizing nanocrystals
AU4305101A (en) * 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7179660B1 (en) 2000-03-06 2007-02-20 Dade Behring Marburg Gmbh Carriers coated with polysaccharides, their preparation and use
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
WO2001082899A2 (en) * 2000-05-03 2001-11-08 Mbt Munich Biotechnology Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US6689338B2 (en) * 2000-06-01 2004-02-10 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
US20050013775A1 (en) * 2000-06-01 2005-01-20 Kotov Nicholas A. Bioconjugates of nanoparticles as radiopharmaceuticals
US6690962B2 (en) * 2000-09-15 2004-02-10 Institut fur Diagnostikforshung GmbH Process for graphic visualization and diagnosis of thrombi by means of nuclear spin tomography with use of particulate contrast media
US8088358B2 (en) 2001-03-08 2012-01-03 Centrum Fur Angewandte Nanotechnologie (Can) Gmbh Paramagnetic nanoparticle
US7081489B2 (en) * 2001-08-09 2006-07-25 Florida State University Research Foundation Polymeric encapsulation of nanoparticles
DE10154016B4 (de) * 2001-10-26 2004-02-12 Berlin Heart Ag Magnetflüssigkeit und Verfahren zur ihrer Herstellung
WO2003066066A1 (en) * 2002-02-01 2003-08-14 Vanderbilt University Targeted drug delivery methods
US20030185757A1 (en) * 2002-03-27 2003-10-02 Mayk Kresse Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
US20030190475A1 (en) * 2002-04-09 2003-10-09 Everett Carpenter Magnetic nanoparticles having passivated metallic cores
US6962685B2 (en) 2002-04-17 2005-11-08 International Business Machines Corporation Synthesis of magnetite nanoparticles and the process of forming Fe-based nanomaterials
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040096089A1 (en) * 2002-08-16 2004-05-20 David Borsook Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US20040058457A1 (en) * 2002-08-29 2004-03-25 Xueying Huang Functionalized nanoparticles
US20050064508A1 (en) * 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
US6989196B2 (en) * 2002-10-02 2006-01-24 Florida State University Research Foundation Microencapsulation of magnetic material using heat stabilization
WO2004083902A2 (en) * 2002-10-25 2004-09-30 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
GB0227738D0 (en) * 2002-11-28 2003-01-08 Univ Liverpool Nanoparticle conjugates and method of production thereof
AU2003900335A0 (en) * 2003-01-22 2003-02-13 Sirtex Medical Limited Microparticles for selectively targeted hyperthermia
DE10331439B3 (de) * 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
US7235228B2 (en) * 2003-04-15 2007-06-26 The United States Of America As Represented By The Secretary Of The Navy Fluorescent-magnetic nanoparticles with core-shell structure
US20070003975A1 (en) * 2003-05-02 2007-01-04 Canon Kabushiki Kaisha Structured construct and producing method therefor
KR100936269B1 (ko) * 2003-06-07 2010-01-12 연세대학교 산학협력단 자성체-고분자 입자 및 그의 제조방법
US8651113B2 (en) * 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7723311B2 (en) * 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
US7344887B2 (en) * 2003-06-24 2008-03-18 Johns Hopkins University Methods and products for delivering biological molecules to cells using multicomponent nanostructures
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
GB0316912D0 (en) 2003-07-18 2003-08-20 Oxford Instr Superconductivity Therapeutic treatment
US20050031544A1 (en) * 2003-08-07 2005-02-10 Njemanze Philip Chidi Receptor mediated nanoscale copolymer assemblies for diagnostic imaging and therapeutic management of hyperlipidemia and infectious diseases
CA2535510C (en) * 2003-08-11 2013-10-15 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
DE10354361A1 (de) * 2003-11-20 2005-06-23 Eberhard-Karls-Universität Tübingen Vorrichtung zum Einbringen in mittels Kernspinresonanztomografie untersuchbares Körpergewebe
WO2005060610A2 (en) * 2003-12-11 2005-07-07 The Trustees Of Columbia University In The City Ofnew York Nano-sized particles, processes of making, compositions and uses thereof
US7795041B2 (en) * 2004-02-11 2010-09-14 Massachusetts Institute Of Technology Multi-polymer-coated magnetic nanoclusters
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US8562505B2 (en) * 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
DE102004010387A1 (de) * 2004-03-03 2005-09-22 Siemens Ag Kontrastmittel für die Röntgen-Computertomographie
JP2005296942A (ja) * 2004-03-15 2005-10-27 Hitachi Maxell Ltd 磁性複合粒子およびその製造方法
WO2005087367A1 (ja) * 2004-03-15 2005-09-22 Hitachi Maxell, Ltd. 磁性複合粒子およびその製造方法
US7842281B2 (en) * 2004-05-10 2010-11-30 The Florida State University Research Foundation Magnetic particle composition for therapeutic hyperthermia
DE102004052533A1 (de) * 2004-10-15 2006-05-04 Mykhaylyk, Olga, Dr. Magnetische Partikel zur Verwendung in Therapie und Diagnostik
CN103060444B (zh) 2004-10-27 2016-01-13 塞弗德公司 多阶段核酸扩增反应
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US20060140867A1 (en) * 2004-12-28 2006-06-29 Helfer Jeffrey L Coated stent assembly and coating materials
DE102005016873A1 (de) * 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
WO2006113668A1 (en) * 2005-04-15 2006-10-26 University Of South Florida A method of transdermal drug delivery using hyaluronic acid nanoparticles
EP1721603A1 (en) * 2005-05-11 2006-11-15 Albert-Ludwigs-Universität Freiburg Nanoparticles for bioconjugation
WO2006125452A1 (en) * 2005-05-23 2006-11-30 Universite De Geneve Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
US20060281104A1 (en) * 2005-06-13 2006-12-14 Macevicz Stephen C Leuco dye particles and uses thereof
KR100806669B1 (ko) * 2005-06-23 2008-02-26 김정환 나노 입자-생체 복합체
WO2007002732A1 (en) * 2005-06-28 2007-01-04 Joslin Diabetes Center, Inc. Methods of imaging inflammation in pancreatic islets
US20070009436A1 (en) * 2005-07-08 2007-01-11 Rondinone Adam J Radionuclide nanoparticles encased by inorganic shell having vector biomolecules attached thereto
EP1743530B1 (en) * 2005-07-15 2011-08-31 Unilever N.V. Iron fortified food product and additive
CZ301067B6 (cs) * 2006-02-24 2009-10-29 Ústav makromolekulární chemie AV CR Superparamagnetické nanocástice na bázi oxidu železa s modifikovaným povrchem, zpusob jejich prípravy a použití
CA2650021A1 (en) * 2006-04-21 2007-11-01 The Children's Hospital Of Philadelphia Magnetic gradient targeting and sequestering of therapeutic formulations and therapeutic systems thereof
JP5282031B2 (ja) * 2006-05-15 2013-09-04 ドミトリィ ビー カーポティン 有機物を含む磁性微粒子
KR100827292B1 (ko) * 2006-05-30 2008-05-07 애니젠 주식회사 실리콘-포함 수용성 고분자로 코팅된 나노입자 및 그의조영제로서의 용도
US8119352B2 (en) * 2006-06-20 2012-02-21 Cepheld Multi-stage amplification reactions by control of sequence replication times
US20080014285A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
US20090297626A1 (en) * 2006-11-03 2009-12-03 The Trustees Of Columbia University In The City Of New York Methods for preparing metal oxides
CA2672810C (en) * 2006-12-18 2015-06-02 Colorobbia Italia S.P.A. Magnetic nanoparticles for the application in hyperthermia, preparation thereof and use in constructs having a pharmacological application
BRPI0806727B8 (pt) 2007-01-21 2021-06-22 Hemoteq Ag método para o revestimento de um cateter de balão
KR100809402B1 (ko) * 2007-01-29 2008-03-05 김정환 나노 입자 표지, 나노 입자 표지를 이용하는 진단 키트, 및진단 방법
US8239008B2 (en) * 2007-04-13 2012-08-07 Ethicon Endo-Surgery, Inc. Sentinel node identification using fluorescent nanoparticles
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
AU2008278605A1 (en) * 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
EP2022508A1 (en) * 2007-08-07 2009-02-11 Charité-Universitätsmedizin Berlin Production of targeted MRI probes by biocompatible coupling of macromolecules with charged nanoparticles
WO2009031859A2 (en) * 2007-09-06 2009-03-12 Anygen Co., Ltd. Multi-functional complex for imaging and drug delivery
WO2009061456A2 (en) * 2007-11-07 2009-05-14 University Of Houston Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof
US20090157069A1 (en) * 2007-12-06 2009-06-18 Curtis Tom Systems and methods for thermal treatment of body tissue
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
JP2009256286A (ja) * 2008-04-21 2009-11-05 Fujifilm Corp 常磁性金属化合物含有ポリマー粒子
US20100018674A1 (en) * 2008-07-22 2010-01-28 Donald John Enzinna Reservoir with moveable partition for quick recovery
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
US20120107229A1 (en) * 2009-04-15 2012-05-03 Xuefei Huang Novel nano-probes for molecular imaging and targeted therapy of diseases
US8383025B2 (en) * 2009-05-19 2013-02-26 Nanyang Technological University Method of manufacturing micro patterned device and device obtained by the method
WO2011005421A2 (en) 2009-07-10 2011-01-13 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
US10080821B2 (en) * 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US20110054236A1 (en) * 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
EP2322142B1 (de) * 2009-11-12 2016-07-27 Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH Biokompatible, magnetische Nanopartikel zur Behandlung von Glioblastomen
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
US20110160645A1 (en) * 2009-12-31 2011-06-30 Boston Scientific Scimed, Inc. Cryo Activated Drug Delivery and Cutting Balloons
KR101057484B1 (ko) * 2010-03-19 2011-08-17 강원대학교산학협력단 소장의 조영을 위한 경구용 조영제
WO2012031236A1 (en) 2010-09-02 2012-03-08 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US10398668B2 (en) 2010-10-19 2019-09-03 The Board Of Regents Of The University Of Oklahoma Glutamate treatment of cardiovascular disorders
US8740872B2 (en) 2010-10-19 2014-06-03 The Board Of Regents Of The University Of Oklahoma Magnetically-targeted treatment for cardiac disorders
US9744235B2 (en) 2010-10-19 2017-08-29 The Board Of Regents Of The University Of Oklahoma Treatment of cardiovascular disorders with targeted nanoparticles
KR101297815B1 (ko) 2010-11-18 2013-09-03 충남대학교산학협력단 폴리감마글루탐산과 광학영상다이의 복합체를 함유하는 센티넬 림프노드 감지용 광학영상 프로브
US8197471B1 (en) * 2011-02-14 2012-06-12 Samuel Harry Tersigni Core-excited nanoparticles and methods of their use in the diagnosis and treatment of disease
EP2675486A2 (en) 2011-02-15 2013-12-25 Semmelweis Egyetem Prussian blue based nanoparticle as multimodal imaging contrast material
KR101398214B1 (ko) * 2011-04-06 2014-05-23 주식회사 바이오리더스 음이온성 고분자와 양이온성 고분자 이온복합체 기반 고감도 자기공명영상 나노조영제 및 이의 제조방법
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
WO2013022458A1 (en) 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
WO2013077476A1 (ko) 2011-11-21 2013-05-30 한국과학기술원 카테콜기가 결합된 키토산 또는 폴리아민 및 말단에 티올기가 결합된 폴락소머를 포함하는 하이드로젤 및 이의 제조방법 및 이를 이용한 지혈제
EP2647389A1 (en) 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use
US8873041B1 (en) 2013-01-29 2014-10-28 Bayspec, Inc. Raman spectroscopy using multiple excitation wavelengths
WO2014132107A1 (en) * 2013-02-27 2014-09-04 Empire Technology Development Llc Preparation and use of magnetic polymer nanocomposites
EP2823858A1 (en) * 2013-07-12 2015-01-14 Brossel, Rémy System generating a constraint field, and medical device implementing the same
US20150064107A1 (en) * 2013-09-04 2015-03-05 King's College London Imaging agent
DE102014106603A1 (de) 2014-05-12 2015-11-12 Verein zur Förderung von Innovationen durch Forschung, Entwicklung und Technologietransfer e.V. (Verein INNOVENT e.V.) Verfahren und Vorrichtung zur Abreicherung von zirkulierenden Tumorzellen aus einer Zellsuspension
US10059621B2 (en) * 2016-05-27 2018-08-28 Corning Incorporated Magnetizable glass ceramic composition and methods thereof
US20170342383A1 (en) 2016-05-27 2017-11-30 Corning Incorporated Lithium disilicate glass-ceramic compositions and methods thereof
WO2019108556A1 (en) 2017-11-28 2019-06-06 Corning Incorporated Bioactive glass compositions and dentin hypersensitivity remediation
US10857259B2 (en) 2017-11-28 2020-12-08 Corning Incorporated Chemically strengthened bioactive glass-ceramics
WO2019108558A1 (en) 2017-11-28 2019-06-06 Corning Incorporated High liquidus viscosity bioactive glass
WO2020174476A1 (en) * 2019-02-28 2020-09-03 Hadasit Medical Research Services And Development Ltd. Targeted magnetic vehicles and method of using the same
CN111330023B (zh) * 2020-03-23 2023-01-31 中国科学院宁波材料技术与工程研究所慈溪生物医学工程研究所 一种磁性纳米复合材料及其制备方法与应用
DE102020116859A1 (de) 2020-06-26 2021-12-30 Pharma Development Holding Gmbh Liposomen
CN112402389A (zh) * 2020-11-24 2021-02-26 常州欧法玛制药技术有限公司 一种唑吡坦双层渗透泵控释片及其制备方法
CN112870387B (zh) * 2021-02-26 2023-08-29 中山大学孙逸仙纪念医院 一种磁性纳米药物载体及其制备方法和应用
WO2023245000A2 (en) * 2022-06-13 2023-12-21 Russell Van De Casteele Methods for processing, enrichment, delivery, formulation, uptake and testing for supplements and pharmaceuticals

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5913521B2 (ja) * 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4323056A (en) * 1980-05-19 1982-04-06 Corning Glass Works Radio frequency induced hyperthermia for tumor therapy
US4501726A (en) * 1981-11-12 1985-02-26 Schroeder Ulf Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
SE8201972L (sv) * 1982-03-29 1983-09-30 Gambro Lundia Ab Magnetiskt paverkbara kristalliserade kolhydrat sferer eller partiklar att anvendas tillsammans med bioadsorberande material
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
JPS59195161A (ja) * 1983-04-21 1984-11-06 Fujirebio Inc 磁性粒子及びその製造法
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
US5720939A (en) * 1985-08-15 1998-02-24 Nycomed Imaging As Method of contrast enhanced magnetic resonance imaging using magnetically responsive-particles
US4788281A (en) * 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
JPS60260463A (ja) * 1984-06-01 1985-12-23 松下電器産業株式会社 高密度酸化物焼結体の製造方法
SE454885B (sv) * 1984-10-19 1988-06-06 Exploaterings Ab Tbf Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav
DE3577185D1 (de) * 1984-11-01 1990-05-23 Nycomed As Paramagnetische kontrastmittel fuer die anwendung in "in vivo" nmr-diagnostischen methoden und die herstellung davon.
HU200104B (en) * 1986-04-07 1990-04-28 Francois Dietlin New contrast composition for tomodensitometry
US5352432A (en) * 1986-07-03 1994-10-04 Advanced Magnetics, Inc. Hepatocyte specific composition and their use as diagnostic imaging agents
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5679323A (en) * 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
DE3729697A1 (de) * 1987-09-04 1989-03-23 Siemens Ag Verfahren zur herstellung von pressfaehigem granulat fuer die fertigung von oxidkeramischen produkten, insbesondere mangan-zink-ferriten
US5395688A (en) * 1987-10-26 1995-03-07 Baxter Diagnostics Inc. Magnetically responsive fluorescent polymer particles
EP0381742B1 (en) * 1988-08-04 1996-06-19 Advanced Magnetics Incorporated Receptor mediated endocytosis type mri contrast agents
JPH0678247B2 (ja) * 1988-10-04 1994-10-05 大塚製薬株式会社 Ｎｍｒ造影用鉄含有製剤
US5612019A (en) * 1988-12-19 1997-03-18 Gordon, Deceased; David Diagnosis and treatment of HIV viral infection using magnetic metal transferrin particles
US5393525A (en) * 1989-07-21 1995-02-28 Nycomed Imaging As Contrast medium comprising superparamagnetic or ferromagnetic particles capable of increasing viscosity after administration
JP2726520B2 (ja) * 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体
US5389377A (en) * 1989-12-22 1995-02-14 Molecular Bioquest, Inc. Solid care therapeutic compositions and methods for making same
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
IL98744A0 (en) * 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
AU652804B2 (en) * 1991-01-19 1994-09-08 Meito Sangyo Kabushiki Kaisha Composition containing ultrafine particles of magnetic metal oxide
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
WO1992022586A1 (en) * 1991-06-11 1992-12-23 Meito Sangyo Kabushiki Kaisha Oxidized composite comprising water-soluble carboxypolysaccharide and magnetic iron oxide
JP3189154B2 (ja) * 1991-07-18 2001-07-16 東ソー株式会社 免疫測定用担体の製造方法
CA2137145A1 (en) * 1992-06-08 1993-12-23 Mark S. Chagnon Preparation of controlled size inorganic particles for use in separations, as magnetic molecular switches, and as inorganic liposomes for medical applications
JP3337075B2 (ja) * 1992-08-05 2002-10-21 名糖産業株式会社 小粒子径水溶性カルボキシ多糖−磁性酸化鉄複合体
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
DE4301871A1 (de) * 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
EP0634174A1 (en) * 1993-07-13 1995-01-18 Takeda Chemical Industries, Ltd. Antianemic composition for veterinary use
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie

Also Published As

Publication number Publication date
IL114713A (en) 2000-02-17
US6048515A (en) 2000-04-11
CN1103604C (zh) 2003-03-26
DE4428851C2 (de) 2000-05-04
EP0773796A1 (de) 1997-05-21
HUT77993A (hu) 1999-04-28
IL114713A0 (en) 1995-11-27
AU2921095A (en) 1996-03-04
CA2195318A1 (en) 1996-02-15
WO1996004017A1 (de) 1996-02-15
KR100278513B1 (ko) 2001-01-15
NO970468D0 (no) 1997-02-03
KR970704476A (ko) 1997-09-06
ZA956005B (en) 1996-02-22
US20020141943A1 (en) 2002-10-03
US6576221B1 (en) 2003-06-10
AU703042B2 (en) 1999-03-11
JPH10503496A (ja) 1998-03-31
CN1155844A (zh) 1997-07-30
DE4428851A1 (de) 1996-02-08
NO314785B1 (no) 2003-05-26
CA2195318C (en) 2002-11-12

Similar Documents

Publication Publication Date Title
NO970468L (no) Jernholdige nanopartikler med dobbelt belegning og deres anvendelse i diagnostikk og terapi
NO942283L (no) Pyrofeoforbider og deres anvendelse i fotodynamisk terapi
EE9700039A (et) Teraapias kasutatavad spiro-asabitsüklilised ühendid ja nende valmistamise protsess
NO2008002I2 (no) Protiokonazol og salter derav
FI970357A (fi) Tyypin II diabeteksen hoitoon käyttökelpoisia bensoksatsoli- ja pyridiinijohdannaisia
NO964958D0 (no) Aluminium-scandiumlegeringer og deres anvendelse
EE9700209A (et) Dihüdropürimidiinid ja nende kasutamine
DE69617008T2 (de) Würfeleckiger körper mit erweitertem öffnungswinkel in einer oder mehreren flächen
NO982913D0 (no) Kinolin- og kinazolinforbindelser nyttige i terapi
AP2002002393A0 (en) Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
NO954944L (no) Antikorrosjonspigment og anvendelse derav
EE9700288A (et) Asatsükloalkaani derivaadid, nende valmistamine ja kasutamine ravis
FI964911A0 (fi) Parannuksia elintarviketuotteiden valmistamiseen ja siihen liittyen
NO984836L (no) Substituerte benzylaminer og deres anvendelse for behandling av depresjon
NO20000462D0 (no) 4-okso-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid derivater, deres fremstilling og deres anvendelse i terapi
GB9419553D0 (en) Polypeptides and their use in the treatment of auto-immune disease
GB9325297D0 (en) Improvements in or relating to clamps and the use thereof
FI940186A (fi) 9H-imidatso/1,2-a/bentsimidatsoli-3-asetamidijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
FI954964A0 (fi) vWF-pitoisten konsentraattien käyttö yhdistelmäterapiana antitromboottisilla ja fibrinolyyttisillä lääkeaineilla suoritettavassa terapiassa
IL131127A0 (en) 2-Amino substituted pyridines for use in the treatment of arteriosclerosis and hyperlipoproteinaemia
IL128902A0 (en) N-(2-benzothiazolyl)-1-piperidineethanamine derivatives their preparation and their use in therapy
IS4387A (is) Nýtt skömmtunarform hýdroxókóbalamíns og notkun þess við sýaníðeitrunum
ZA983740B (en) Novel amidine derivatives and their use in therapy
IL123156A0 (en) Benzenesulphonamide derivatives their preparation and their application in therapy
NZ293994A (en) Immortalized endothelial brain cell lines and their use in therapy

Legal Events

Date Code Title Description
CB Opposition filed (par. 26,5 patents act)

Opponent name: AMERSHAM HEALTH AS, POSTBOKS 4220 NYDALEN, OSLO, 0

Effective date: 20040226

MM1K Lapsed by not paying the annual fees